- Details
- In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signaling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. In the quality-of-life anal...
|
- Details
- Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc, discuss the recently published data (Lancet Oncology) from the CARD trial "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide." Previously reported from the CARD Study in the NEJM cabazitaxel significantly improved radiographic progression-free survival and o...
|
- Details
- Alicia Morgans, MD, MPH presents a State of Art Lecture on treatment selection for mCRPC patients who have disease progression progressing after combination treatment for in metastatic castration-sensitive prostate cancer (mCSPC). The learning objectives of this presentation include to understand the rationale for avoiding sequencing of androgen receptor-targeted agents one after another, how to c...
|
- Details
- Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020 Virtual...
|
- Details
- Cora Sternberg, MD, FACP, shares her experiences from the CARD study, which was the first trial to evaluate the sequencing of the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) compared to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abi...
|
- Details
- William Oh and Stephen Freedland join Alicia Morgans to discuss the efficacy and safety in older patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide an analysis of the CARD Trial. Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively, with most deaths occurring in men over t...
|
- Details
- Lead author of the TRITON-2 study, Wassim Abida joins Charles Ryan to talk about the recent approval of rucaparib, the first PARP Inhibitor approved for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. This approval was based on findings from the TRITON-2 study, rucaparib for post-chemotherapy mCRPC patients who have previously received one AR-targe...
|
- Details
- Alicia Morgans and Christopher Sweeney discuss the IMbassador250 trial results presented at the AACR 2020 virtual meeting. IMbassador250 is a phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone. Dr. Sweeney says that the study conclusively showed that adding atezolizumab to enzalutamide after abirat...
|
- Details
- Charles Ryan invites Rahul Aggarwal to discuss treatment-emergent small-cell neuroendocrine prostate cancer, an area not well characterized in the era of modern androgen receptor (AR)-targeting therapy. This study was funded by Stand Up to Cancer and the Prostate Cancer Foundation. Patients with metastatic castration-resistant prostate cancer were enrolled in which metastatic tumor biopsies were p...
|
- Details
- Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration (FDA) approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-res...
|
